WHITE RIVER JUNCTION, VT. JULY 10, 2018
The Foundation has Shared with GSK its Report Submitted to FDA in Advance of the July 12, 2018 Meeting of the Antimicrobial Drugs Advisory Committee at Which New Drug Application (NDA) 210795 Will be Considered
WHITE RIVER JUNCTION, VT. JUNE 26, 2018
Veterans and VA Health Care Providers Must Be Provided With Up-To-Date Information That Accurately Reflects the Health Risks Posed by the Neurotoxic Drug
WHITE RIVER JUNCTION, VT. MAY 29, 2018
The Antimalarial Drug Can Cause Chronic Neurologic and Psychiatric Effects Among Some Veterans, but the Government Does Not Know How Many Veterans Were Exposed, and Which Veterans Are Suffering Symptoms of Poisoning from their Exposure
The term "quinism" may seem new, but no doubt the symptoms of poisoning by mefloquine, tafenoquine, and related quinoline drugs are all too familiar: Tinnitus. Dizziness. Vertigo. Paresthesias. Visual disturbances. Gastroesophageal and intestinal problems. Nightmares. Insomnia. Anxiety. Cognitive dysfunction. Depression. Personality change. Suicidal thoughts.
These symptoms are not 'side effects'. They are symptoms of poisoning by a class of drug that is neurotoxic and that injures the brain and brainstem. Poisoning that causes a disease.
This disease has a name. The disease is chronic quinoline encephalopathy — also known as neuropsychiatric quinism.
The Quinism Foundation is a Vermont domestic 501(c)(3) nonprofit charitable organization established to support education and research on chronic quinoline encephalopathy and other medical conditions caused by poisoning, or intoxication, by mefloquine, tafenoquine, and related quinoline drugs.
The foundation has an enormous job ahead. We must prepare healthcare organizations to identify those exposed to quinolines. We must educate clinicians to diagnose chronic quinoline encephalopathy and other medical conditions caused by quinoline poisoning. We must train researchers to distinguish the effects of quinism from those of other disorders. We must assist government agencies to recognize those suffering disability from quinism. We must identify risk factors for the disease. We must attempt to count all those affected. And, we must support a search for effective treatments.
Please take a moment to sign up for our mailing list. In the coming weeks, you will begin to receive regular updates from the foundation. You will also learn about how to get involved and support the foundation's activities. The foundation is proud to be listed as a registered charity in the PayPal Giving Fund, on Amazon Smile, and in the Facebook donor-advised fund. You can also read more about the foundation’s charitable activities by reviewing our listing on Guidestar.
In the meantime, you can learn more by reading this press release announcing the foundation's incorporation.
On behalf of The Quinism Foundation, I thank you in advance for your support. I am confident that together, we can make a difference in the fight against quinism. I hope that you will join us.
Remington Nevin, MD, MPH, DrPH
Executive Director, The Quinism Foundation